Objectives: Acute kidney injury is a common complication after aortic surgery. Carperitide, a human atrial natriuretic peptide, was reported to be effective for preventing acute kidney injury after cardiac surgery. However, most studies were from single centers, and results of meta-analyses are subject to publication bias. The aim of the present study was to investigate whether carperitide preserved renal function in patients undergoing cardiovascular surgery.
Design: Retrospective cohort study.
Setting: Participating hospitals (N = 281) in a national database from 2010 to 2013.
Participants: Adult patients (N = 47,032) who underwent cardiovascular surgery.
Interventions: None.
Measurements and main results: The main intervention variable investigated was the use of carperitide on the day of surgery. Assessed outcomes included receiving renal replacement therapy within 21 days of surgery and in-hospital mortality. Data were available for 47,032 patients, of whom 2,186 (4.6%) received carperitide on the day of surgery. Multivariate logistic regression analysis revealed that carperitide was significantly associated with a greater likelihood of receiving renal replacement therapy within 21 days of surgery, but not with in-hospital mortality.
Conclusions: In patients undergoing cardiovascular surgery, carperitide significantly increased the odds of receiving renal replacement therapy within 21 days after surgery.
Keywords: atrial natriuetic peptide; cardiovascular surgery; carperitide; mortality; perioperative care; renal failure; renal replacement therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.